7 Best NASDAQ Stocks Under $5

4. Verve Therapeutics, Inc. (NASDAQ:VERV)

Stock Price as of September 27: $4.98

Number of Hedge Fund Holders: 26

Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company focused on revolutionizing the treatment of cardiovascular disease through innovative gene-editing approaches. The company takes 4th place among our current list of best NASDAQ stocks under $5.

Rather than relying on chronic management therapies, it aims to develop single-course genetic medicines that can significantly lower low-density lipoprotein cholesterol (LDL-C), a key contributor to cardiovascular issues. The company’s pipeline includes three promising programs, VERVE-101, VERVE-102, and VERVE-201, each targeting well-validated genes for cholesterol reduction.

Dr. Sekar Kathiresan, co-founder and CEO of Verve Therapeutics (NASDAQ:VERV), emphasizes the importance of not only reducing cholesterol levels but also maintaining that reduction over time. Current therapies often fail to provide sustained cholesterol control for many patients, creating a significant unmet need.

The company is dedicated to addressing this gap, positioning itself to establish a new standard of care for millions of individuals suffering from heart disease. With a strong financial foundation that is expected to support operations through late 2026, the company is well-equipped to pursue this ambitious vision.

The second quarter of the year has seen Verve Therapeutics (NASDAQ:VERV) make significant strides in its clinical development efforts. The Heart-2 Phase 1b trial of VERVE-102 is progressing steadily, with a focus on patient enrollment and expanding the trial’s reach, especially with regulatory approval to operate in Australia.

Initial results from this trial are expected in the first half of 2025, which marks an important step forward in the development of its gene-editing therapies. Additionally, the initiation of the Phase 1b clinical trial for VERVE-201, targeting the ANGPTL3 gene, is set to initiate in the latter half of this year.